Adding Boceprevir Improves Virologic Response in Chronic HCV-1

In both of these clinical trials, patients who showed undetectable levels of HCV RNA at week 8 also showed a high rate of sustained virologic response, regardless of which treatment they received. This confirms that a strong early response to treatment is predictive of a sustained virologic response, both groups of researchers said.

Both of these studies were funded by Schering-Plough (now part of Merck). Both groups of investigators reported ties to numerous industry sources, including Shering-Plough/Merck.